Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointments - UK Ventures

25 Oct 2005 08:00

Angle PLC25 October 2005 For Immediate Release 25 October 2005 ANGLE plc Appointments - UK Ventures ANGLE is pleased to announce that Dr Stephen Bence and John Holden have beenappointed Directors of ANGLE's UK Ventures arm from the position of AssociateDirectors, with immediate effect. Stephen will have broad responsibility foridentifying intellectual property with commercial potential, securing accessto it and developing business plans to exploit it, while John will beresponsible for ventures development encompassing business plan implementation,funding and final stage realisation. Commenting on these appointments, Stephen Bates, UK Chief Executive of ANGLE,said: "Stephen and John have proved to be enormously valuable in the development ofANGLE's UK Ventures business so far in 2005. I am delighted to be announcingthese appointments and am looking forward to continued success with them." Enquiries: ANGLE plc 01483 295830Andrew Newland, Group CEOStephen Bates, CEO UK Ventures Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM
29th Oct 20187:00 amRNSPARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25th Oct 20187:00 amRNSGood Progress with FDA Studies
9th Oct 20187:00 amRNSNotice of AGM
28th Aug 20187:00 amRNSParsortix shows evidence of CTCs in glioblastoma
25th Jul 20187:00 amRNSPreliminary Results for year ended 30 April 2018
24th Jul 20185:42 pmRNSEIS/VCT Advance Assurance and Total Voting Rights
18th Jul 201810:34 amRNSResult of General Meeting
2nd Jul 20187:00 amRNSNotice of Preliminary Results
25th Jun 20186:20 pmRNSResults of Fundraising
25th Jun 20182:58 pmRNSClose of Accelerated Bookbuild
25th Jun 20187:50 amRNSProposed Placing of New Ordinary Shares
4th Jun 20187:00 amRNSENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
14th May 20187:00 amRNSLeading cancer surgeon appointed
3rd May 20187:00 amRNSAngle & QIAGEN Poster
19th Apr 20187:00 amRNSParsortix in multiple presentations at AACR
19th Apr 20187:00 amRNSBreakthrough Research with Parsortix
5th Apr 20187:00 amRNSFirst patient enrolled in FDA study
26th Mar 20184:35 pmRNSPrice Monitoring Extension
26th Mar 20187:00 amRNSResearch Update
6th Feb 20187:00 amRNSANGLE plc: RESEARCH GRANT FROM ABBOTT
31st Jan 20187:00 amRNSInterim Results
16th Jan 20187:00 amRNSWEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
10th Jan 201810:16 amRNSNotice of Results
8th Jan 20187:00 amRNSANGLE plc:Prostate cancer ARV7 treatment biomarker
27th Dec 201711:49 amRNSHolding(s) in Company
12th Dec 20177:00 amRNSTransfer of Lock-in Shares
8th Dec 20177:00 amRNSPARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
28th Nov 20177:00 amRNSParsortix enables CTC molecular characterisation
23rd Nov 20177:00 amRNSPHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17th Nov 20174:06 pmRNSHolding(s) in Company
16th Nov 20178:23 amRNSTotal Voting Rights and Covington Subscription
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 201710:04 amRNSHolding(s) in Company
1st Nov 20178:12 amRNSANGLE: Completion of Fundraising and Acquisition
31st Oct 20172:18 pmRNSResult of AGM
30th Oct 201710:31 amRNSResult of General Meeting
26th Oct 20178:10 amRNSTotal Voting Rights
23rd Oct 20177:00 amRNSParsortix harvests cancer cells from bone marrow
20th Oct 20173:05 pmRNSNotice of AGM
17th Oct 20177:00 amRNSANGLE: 7th Peer Reviewed Publication On Parsortix
12th Oct 20177:00 amRNSProposed further subscription for £2.8 million
9th Oct 20177:02 amRNSCTCs harvested with Parsortix grown in laboratory
9th Oct 20177:01 amRNSPotential new analytical protocol using Parsortix
9th Oct 20177:00 amRNSParsortix Showcased at CTC Conference
5th Oct 201711:46 amRNSResults of Fundraising
5th Oct 20177:00 amRNSAcquisition and Fundraising

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.